INVO Fertility Confirms New Nasdaq Trading Symbol of "IVF"
MWN-AI** Summary
INVO Fertility, Inc. (Nasdaq: NAYA), previously known as NAYA Biosciences, has announced an updated trading symbol of "IVF," which will take effect on April 28, 2025. This change aligns with the company's strategic decision made on April 14, 2025, to separate its fertility and oncology operations, allowing a sharper focus on its core business of fertility care.
Steve Shum, CEO of INVO Fertility, expressed how the new ticker symbol encapsulates their ongoing commitment to the fertility sector. The company aims to expand access to advanced fertility treatments by establishing, acquiring, and operating clinics across the United States. This initiative comes in light of a recent executive order by the U.S. President aimed at reducing the costs of In Vitro Fertilization (IVF) and broadening access to fertility services, enhancing the company's mission of helping individuals realize their family aspirations.
INVO Fertility operates two INVO Centers in the U.S. and one IVF clinic, and its primary commercial strategy revolves around the innovative intravaginal culture (IVC) procedure enabled by the proprietary INVOcell device. Unlike traditional IVF procedures, the IVC allows for fertilization and early embryo development to occur in vivo, offering patients a more natural and intimate experience at a lower cost while maintaining comparable success rates.
The CUSIP number of INVO Fertility's common stock remains unchanged, and the company emphasizes a forward-looking approach while noting that their projections are subject to various risks and uncertainties. For additional details about INVO Fertility and its services, interested parties can visit their official website at www.invobio.com.
MWN-AI** Analysis
As INVO Fertility prepares to transition to its new Nasdaq trading symbol "IVF" on April 28, 2025, investors should remain cognizant of both the opportunities and potential challenges associated with this strategic shift. The company’s focus on advancing fertility care amidst a rising demand for assisted reproductive technologies (ART) positions it favorably in a growing market; however, the path forward is not without risks.
The change in ticker symbolizes INVO’s commitment to concentrating on fertility services, separating from its oncology operations. This strategic realignment could enhance resource allocation, improve operational efficiencies, and ultimately drive shareholder value. The announcement of supportive policies, such as the U.S. President's executive order aimed at reducing IVF costs and expanding access to these services, further complements INVO's efforts. Investors should assess the potential for increased patient volume and revenues stemming from these favorable regulatory developments.
However, the market must also factor in competitive dynamics and the execution risks that accompany operational expansions. With only two operational INVO Centers and one IVF clinic to date, meeting growing demand while maintaining service quality will be critical. Furthermore, the success of the INVOcell technology, a hallmark of INVO's offering, relies on patient acceptance and clinical efficacy compared to more prevalent ART methods.
From a technical perspective, investors may want to monitor trading volume and price fluctuations closely as the transition unfolds. A strong open under the new ticker could reinforce market validation of the strategic pivot; ideally, this will attract a broader investor base interested in the burgeoning fertility sector.
In conclusion, while INVO Fertility represents an intriguing investment opportunity with its innovative approach and favorable market conditions, investors should remain cautious and perform due diligence to navigate the inherent risks involved in this evolving landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today confirmed it will begin trading under the new symbol “IVF” at the market open on April 28, 2025.
The CUSIP number for the Company's common stock will remain unchanged.
The symbol change follows the Company’s announcement on April 14, 2025, regarding the strategic decision to separate its fertility and oncology businesses into distinct operations.
“Our new Nasdaq ticker symbol of ‘IVF’ reflects our go-forward business concentration on the fertility care market,” commented Steve Shum, CEO of INVO Fertility. “This change underscores our strategic focus on building, acquiring and operating fertility clinics in the United States and our focus on innovative reproductive services and technologies. As reinforced by the U.S. President’s recent executive order to reduce the cost of IVF and expand access to fertility services, we look forward to refocusing and scaling our mission of helping people build the families of which they dream.”
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by its INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit www.invobio.com .
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov . We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
INVO Fertility
Steve Shum, CEO
978-878-9505
sshum@invobio.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ**
How does the rebranding from NAYA Biosciences Inc. to INVO Fertility, Inc. align with the company's strategic focus on fertility services, and what impact do you anticipate this will have on investor perception?
Given the separation of fertility and oncology businesses, how does INVO Fertility plan to allocate resources and focus its operations while transitioning from NAYA Biosciences Inc.?
What are the projected growth opportunities for INVO Fertility as it adopts the new ticker symbol "IVF," and how does that differ from previous goals under NAYA Biosciences Inc.?
With the introduction of the INVOcell technology, how does INVO Fertility plan to differentiate its offerings in the competitive landscape previously established by NAYA Biosciences Inc.?
**MWN-AI FAQ is based on asking OpenAI questions about NAYA Biosciences Inc. (NASDAQ: NAYA).
NASDAQ: NAYA
NAYA Trading
8.18% G/L:
$2.20 Last:
188,265 Volume:
$2.02 Open:
